 BEIJING CAMBRIDGE, Mass.--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration NMPA for the treatment of patients with germline BRCA gBRCA mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have 